{
  "ticker": "EMD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959563",
  "id": "02959563",
  "pages": 5,
  "price_sensitive": true,
  "date": "20250618",
  "time": "0944",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250618/pdf/06kvqz9l30j156.pdf",
  "summary": "### **Material Information Summary**  \n\n#### **Key Highlights:**  \n- **Medibank Partnership**:  \n  - Multi-year agreement with Medibank (ASX: MPL) to fund PTSD care program at Perth Clinic (no out-of-pocket costs for eligible patients).  \n  - First major private health insurance funding for psychotherapy-led PTSD program in Australia.  \n\n- **Capital Raising**:  \n  - **Structure**: Placement ($4M) + proposed Loyalty Options (1:4 ratio).  \n  - **Price**: $0.024/share (4% discount to last close, 6.15% discount to 15-day VWAP).  \n  - **Key Dates**:  \n    - Tranche 1 (ASX 7.1/7.1A capacity): Settles ~25 June 2025.  \n    - Tranche 2 (subject to EGM): Shareholder approval sought in August 2025.  \n  - **Use of Funds**: National rollout of PTSD programs, working capital.  \n\n- **Expansion Strategy**:  \n  - Plans to establish Empax Centres in Eastern states, partner with more hospitals/funders.  \n  - Program value per patient: $20,000\u2013$30,000 (variable based on clinical needs).  \n\n- **Other Material Terms**:  \n  - Medibank contract has 24-month initial term, 90-day termination clause.  \n  - Independent outcomes research by ANU to validate clinical/economic impact.  \n\n*Omitted: Operational details, director commentary, forward-looking statements.*",
  "usage": {
    "prompt_tokens": 3363,
    "completion_tokens": 321,
    "total_tokens": 3684,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-17T23:59:36.070400"
}